Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2018; 10(03): 271-275
DOI: 10.4103/JLP.JLP_170_17
Original Article

Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study

Hayder M. Al-Kuraishy
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
,
Ali I. Al-Gareeb
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
,
Ali K. Al-Buhadily
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
› Author Affiliations Financial support and sponsorship Nil
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

INTRODUCTION: Rosuvastatin is a lipid-lowering agent that inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase leading to a reduction of cholesterol biosynthesis. Many studies have shown an association between statins use and the reduction of sepsis. The aim of the present study was to evaluate the in vitro combined antibacterial activity of rosuvastatin and cefixime.

MATERIALS AND METHODS: Five pathogenic bacteria isolates (Gram positive and Gram negative) were used for testing the antibacterial activity of rosuvastatin alone and in combination with cefixime.

Results: Rosuvastatin mainly inhibited Klebsiella pneumoniae and Escherichia coli where it caused zones of inhibition of (17.9 ± 0.6 mm) and (16.9 ± 0.3 mm), respectively; however, it moderately inhibited the growth of Staphylococcus epidermidis (12.9 ± 0.2 mm) and Staphylococcus aureus (12.76 ± 0.2) and produced less inhibition for Pseudomonas aeruginosa growth where it led to a zone of inhibition equal to (9.1 ± 0.5 mm). Minimal inhibitory concentration (μg/mL) of rosuvastatin was high compared to cefixime. Fractional inhibitory concentration (FIC) of rosuvastatin was low for E. coli and K. pneumoniae compared to the other types of bacterial strains. Rosuvastatin exhibited additive effects with cefixime against E. coli and K. pneumoniae. ΣFIC index was 0.536 and 0.734 for E. coli and K. pneumoniae, respectively.

Conclusions: Rosuvastatin has a significant antibacterial activity against both Gram-negative and Gram-positive bacteria with a potential additive effect when used in combination with cefixime.

Keywords

Antibacterial activity - cefixime - fractional inhibitory concentration - rosuvastatin


Publication History

Received: 24 November 2017

Accepted: 31 January 2018

Article published online:
19 February 2020

© 2018.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Szekeres E, Baricz A, Chiriac CM, Farkas A, Opris O, Soran ML, et al. Abundance of antibiotics, antibiotic resistance genes and bacterial community composition in wastewater effluents from different Romanian hospitals. Environ Pollut 2017;225:304-15.
  • 2 Khoshnood S, Heidary M, Mirnejad R, Bahramian A, Sedighi M, Mirzaei H, et al. Drug-resistant gram-negative uropathogens: A review. Biomed Pharmacother 2017;94:982-94.
  • 3 Kristiansen JE, Thomsen VF, Martins A, Viveiros M, Amaral L. Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo 2010;24:751-4.
  • 4 Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant gram-negative infections: Mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008;31:198-208.
  • 5 Al-Kuraishy HM, Al-Gareeb AI. Effects of Rosuvastatin alone or in combination with omega-3 fatty acid on adiponectin levels and cardio metabolic profile. J Basic Clin Pharm 2016;8:8-14.
  • 6 Paricahua LI, Goncalves AFO, Pacheco SODS, Pacheco FJ. Sepsis mortality in critical care and prior statin therapy: A Retrospective cohort study in central Argentina. J Clin Diagn Res 2017;11:OC17-21.
  • 7 Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z. Antibacterial activity of statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob 2012;11:13.
  • 8 Sirisolla J, Ramanamurthy KV. Formulation and evaluation of cefixime trihydrate matrix tablets using HPMC, sodium CMC, ethyl cellulose. Indian J Pharm Sci 2015;77:321-7.
  • 9 Shokouhi S, Darazam IA, Zamanian MH. Community-acquired methicillin-resistant Staphylococcus aureus carriage rate and antimicrobial susceptibility in a tertiary center, Iran. J Res Med Sci 2017;22:71.
  • 10 Smaill F. Antibiotic susceptibility and resistance testing: An overview. Can J Gastroenterol 2000;14:871-5.
  • 11 Wei WJ, Yang HF. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: Colistin and chloramphenicol. Int J Antimicrob Agents 2017;49:321-6.
  • 12 Fratini F, Mancini S, Turchi B, Friscia E, Pistelli L, Giusti G, et al. Anovel interpretation of the fractional inhibitory concentration index: The case Origanum vulgare L. And Leptospermum scoparium J. R. et G. Forst essential oils against Staphylococcus aureus strains. Microbiol Res 2017;195:11-7.
  • 13 Brooks BD, Brooks AE. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev 2014;78:14-27.
  • 14 Pereira NL, Aquino PE, Júnior JG, Cristo JS, Vieira Filho MA, Moura FF, et al. Antibacterial activity and antibiotic modulating potential of the essential oil obtained from Eugenia jambolana in association with led lights. J Photochem Photobiol B 2017;174:144-9.
  • 15 Al-Kuraishy HM, Al-Gareeb AI. Experimental antibacterial activity of selective cyclooxygenase antagonist. Int J Basic Clin Pharmacol 2013;2:381-5.
  • 16 Coban AY, Tekeli HO, Güney AK, Durupinar B. Investigation of the in vitro antibacterial effects of statins. Mikrobiyol Bul 2010;44:161-3.
  • 17 Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008;61:362-4.
  • 18 Graziano TS, Cuzzullin MC, Franco GC, Schwartz-Filho HO, de Andrade ED, Groppo FC, et al. Statins and antimicrobial effects: Simvastatin as a potential drug against Staphylococcus aureus biofilm. PLoS One 2015;10:e0128098.
  • 19 Welsh AM, Kruger P, Faoagali J. Antimicrobial action of atorvastatin and rosuvastatin. Pathology 2009;41:689-91.
  • 20 Alagić-Džambić L, Omerović S, Džambić M. Antimicrobial activity of rosuvastatin. Int J Pharm Technol 2015;6:7587-92.
  • 21 Bergman P, Linde C, Pütsep K, Pohanka A, Normark S, Henriques-Normark B, et al. Studies on the antibacterial effects of statins –In vitro and in vivo. PLoS One 2011;6:e24394.
  • 22 Lobato LS, Rosa PS, Ferreira Jda S, Neumann Ada S, da Silva MG, do Nascimento DC, et al. Statins increase rifampin mycobactericidal effect. Antimicrob Agents Chemother 2014;58:5766-74.
  • 23 Skerry C, Pinn ML, Bruiners N, Pine R, Gennaro ML, Karakousis PC, et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J Antimicrob Chemother 2014;69:2453-7.
  • 24 Eisenreich W, Bacher A, Arigoni D, Rohdich F. Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol Life Sci 2004;61:1401-26.
  • 25 Haeri MR, White K, Qharebeglou M, Ansar MM. Cholesterol suppresses antimicrobial effect of statins. Iran J Basic Med Sci 2015;18:1253-6.
  • 26 Biradar YS, Jagatap S, Khandelwal KR, Singhania SS. Exploring of antimicrobial activity of Triphala Mashi-an ayurvedic formulation. Evid Based Complement Alternat Med 2008;5:107-13.
  • 27 Kothe H, Dalhoff K, Rupp J, Müller A, Kreuzer J, Maass M, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000;101:1760-3.
  • 28 Gabr MM, Mortada SM, Sallam MA. Hexagonal liquid crystalline nanodispersions proven superiority for enhanced oral delivery of rosuvastatin:In vitro characterization and in vivo pharmacokinetic study. J Pharm Sci 2017;106:3103-12.
  • 29 Farmer AR, Murray CK, Mende K, Akers KS, Zera WC, Beckius ML, et al. Effect of HMG-coA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods. J Basic Microbiol 2013;53:336-9.
  • 30 Berredjem M, Bouchareb F, Kaki SA, Dekhil M, Aouf NE. Synthesis and antibacterial activity of novel N-acylsulfonamides. Arabian J Chem 2017;10:S1095-9.
  • 31 Renner LD, Weibel DB. Physicochemical regulation of biofilm formation. MRS Bull 2011;36:347-55.
  • 32 Wang D, Shi J, Xiong Y, Hu J, Lin Z, Qiu Y, et al. AQSAR-based mechanistic study on the combined toxicity of antibiotics and quorum sensing inhibitors against Escherichia coli. JHazard Mater 2018;341:438-47.
  • 33 Hennessy E, Adams C, Reen FJ, O'Gara F. Is there potential for repurposing statins as novel antimicrobials? Antimicrob Agents Chemother 2016;60:5111-21.